SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Oscar Health, Inc. (OSCR) has a negative trailing P/E of -9.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 40.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -10.89%, forward earnings yield 2.47%. PEG 0.33 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (78/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.33); analyst target implies upside (+11.2%).
- Forward P/E 40.5 — analysts expect a return to profitability with estimated EPS of $0.38 for FY2026.
- PEG Ratio 0.33 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -10.89% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 2.47% as earnings recover.
- Analyst consensus target $17.00 (+11.2% upside) — modest upside expected.
Overall SharesGrow Score: 40/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
78/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — OSCR
Valuation Multiples
P/E (TTM)-9.2
Forward P/E40.5
PEG Ratio0.33
Forward PEG0.33
P/B Ratio4.16
P/S Ratio0.32
EV/EBITDA-3.5
Per Share Data
EPS (TTM)$-1.56
Forward EPS (Est.)$0.38
Book Value / Share$3.46
Revenue / Share$41.31
FCF / Share$3.74
Yields & Fair Value
Earnings Yield-10.89%
Forward Earnings Yield2.47%
Dividend Yield0.00%
SharesGrow IV$3,319.89 (+21612.8%)
Analyst Target$17.00 (+11.2%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-3.9 |
0.00 |
-1.08 |
1.84 |
- |
| 2020 |
-20.5 |
0.25 |
-6.43 |
14.12 |
- |
| 2021 |
-2.5 |
-0.03 |
1.01 |
0.73 |
- |
| 2022 |
-0.9 |
0.08 |
0.59 |
0.13 |
- |
| 2023 |
-7.5 |
0.13 |
2.52 |
0.35 |
- |
| 2024 |
127.0 |
-1.17 |
3.19 |
0.35 |
- |
| 2025 |
-8.5 |
0.01 |
3.86 |
0.32 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-1.09 |
$553.78M |
$-261.18M |
-47.2% |
| 2020 |
$-1.70 |
$589.64M |
$-406.83M |
-69% |
| 2021 |
$-3.19 |
$1.92B |
$-572.61M |
-29.8% |
| 2022 |
$-2.87 |
$4.13B |
$-606.28M |
-14.7% |
| 2023 |
$-1.22 |
$5.86B |
$-270.73M |
-4.6% |
| 2024 |
$0.10 |
$9.18B |
$25.43M |
0.3% |
| 2025 |
$-1.69 |
$11.7B |
$-443.15M |
-3.8% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$0.38 |
$-1.19 – $1.40 |
$18.72B |
$18.66B – $18.78B |
5 |
| 2027 |
$1.11 |
$-0.11 – $1.86 |
$19.74B |
$18.72B – $20.76B |
6 |
| 2028 |
$1.88 |
$1.22 – $2.31 |
$21.56B |
$21.53B – $21.6B |
3 |
